Keywords: Nektar Thera, Royalty Pharma, UCB, Roche, Cimzia, Mircera, Rheumatoid arthritis, Anemia

Nektar sells Cimzia and Mircera royalty rights for $124 million

Article | 01 March 2012

US biotech firm Nektar Therapeutics (Nasdaq: NKTR) has agreed to sell to Royalty Pharma its royalties on future sales of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in